Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17951146 | 0.93 | MEN1 (0.52) | USP2SMN1; SMN2HPGDEPHX2MEN1 | |
| SCHEMBL18294 | 0.89 | USP2 (0.69) | USP2SMN1; SMN2HPGDEPHX2MEN1 | |
| SCHEMBL698803 | 0.89 | USP2 (0.69) | USP2SMN1; SMN2HPGDEPHX2MEN1 | |
| Pyridine SCHEMBL28262260 | 0.85 | GPR119 (0.47) | USP2SMN1; SMN2POLBGPR119 | |
| SCHEMBL25935474 | 0.83 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL8662177 | 0.83 | USP2 (0.58) | USP2SMN1; SMN2HPGDEPHX2MEN1 | |
| SCHEMBL27388627 | 0.83 | USP2 (0.62) | USP2SMN1; SMN2HPGDEPHX2MEN1 | |
| SCHEMBL16612394 | 0.83 | USP2 (0.62) | USP2SMN1; SMN2HPGDEPHX2MEN1 | |
| Hydrochloric Acid SCHEMBL29190718 | 0.82 | USP2 (0.56) | USP2SMN1; SMN2HPGDEPHX2MEN1 | |
| SCHEMBL2223924 | 0.81 | USP2 (0.60) | USP2SMN1; SMN2HPGDEPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039317-A | Benzenedinitrogen-doped benzothiophene compound, and preparation method and application thereof | 郑州大学 | 2024-11-29 | — | — | CN | claimed |
| EP-4743446-A1 | NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA | Board of Trustees of Michigan State University (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260116855-A1 | ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS | PALATIN TECHNOLOGIES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12478620-B2 | Cyano-substituted cyclic hydrazine derivative and application thereof | E-NITIATE BIOPHARMACEUTICALS (HANGZHOU) CO., LTD (CN) | 2025-11-25 | — | — | US | disclosed |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12459894-B2 | Orally active melanocortin receptor-4 compounds | PALATIN TECHNOLOGIES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| CN-1589270-A | Indole-2-formamide compounds as factor Xa inhibitors | AVENTIS PHARMA GMBH (DE) | 2005-03-02 | — | — | CN | disclosed |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-5807857-A | Piperazine, piperidine and tetrahydropyridine derivative of indol-3-alkyl as 5-HT1D-α agonists | MERCK SHARP & DOHME LTD. (GB) | 1998-09-15 | — | — | US | disclosed |
| WO-1997044328-A1 | 1-(ALKANOYL HALIDE)-2-CARBOXAMIDO-1,4,5,6-TETRAHYDROPYRAZINES | BASF AKTIENGESELLSCHAFT (DE) | 1997-11-27 | — | — | WO | disclosed |
| US-4839358-A | ANALGESICS, ANTIDEPRESSANTS, ANTIANXIETY AGENTS | ROUSSEL UCLAF (FR) | 1989-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459894-B2 | Orally active melanocortin receptor-4 compounds | MC4R, MC1R, MC3R | USP2 4805/4885SMN1; SMN2 1126/4885HPGD 4197/4885 |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | USP2 2527/4885SMN1; SMN2 3736/4885HPGD 3576/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | USP2 1960/4885SMN1; SMN2 4318/4885HPGD 3680/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | USP2 2297/4885SMN1; SMN2 2487/4885HPGD 1097/4885 |
| US-12478620-B2 | Cyano-substituted cyclic hydrazine derivative and application thereof | WNK1, STK35, CDK1 | USP2 2176/4885SMN1; SMN2 4243/4885HPGD 452/4885 |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | USP2 861/4885SMN1; SMN2 4475/4885HPGD 2638/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | USP2 3495/4885SMN1; SMN2 4319/4885HPGD 1381/4885 |
| US-20260116855-A1 | ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS | MC1R, MC3R, MC5R | USP2 3404/4885SMN1; SMN2 2085/4885HPGD 3678/4885 |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | F12, F5, F2 | USP2 3314/4885SMN1; SMN2 4060/4885HPGD 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.